Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31 Maio 2023 - 5:05PM
Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset
clinical-stage biopharmaceutical company, focused on identifying,
developing and commercializing treatments in high unmet need areas
involving rare diseases and multi-drug resistant (MDR) bacterial
infections, today announced that on May 25, 2023, the Compensation
Committee of Spero’s Board of Directors approved the grant of an
aggregate of 90,000 restricted stock unit awards (RSUs) to two new
employees under the Spero Therapeutics, Inc. 2019 Inducement Equity
Incentive Plan, as amended, or the 2019 Inducement Plan. The RSUs
are being granted as inducements material to the new employees
becoming employees of Spero in accordance with Nasdaq Listing
Rule5635(c)(4).
The 2019 Inducement Plan is used exclusively for
the grant of equity awards to individuals who were not previously
employees of Spero (or following a bona fide period of
non-employment), as an inducement material to such individuals'
entering into employment with Spero, pursuant to Rule 5635(c)(4) of
the Nasdaq Listing Rules.
The RSUs will vest in four equal annual
installments beginning on June 1, 2024, subject to the employee's
continued employment with Spero on such vesting dates. The RSUs are
subject to the terms and conditions of the 2019 Inducement Plan and
an RSU agreement covering the grant.
About Spero TherapeuticsSpero
Therapeutics, headquartered in Cambridge, Massachusetts, is a
multi-asset, clinical-stage biopharmaceutical company focused on
identifying, developing, and commercializing novel treatments for
bacterial infections, including multi-drug resistant bacterial
infections and rare diseases.
- Spero Therapeutics is developing SPR720 as a novel oral therapy
candidate for the treatment of a rare, orphan pulmonary disease
caused by non-tuberculous mycobacterial infections.
- Tebipenem HBr is an investigational drug in the United States
being developed for the treatment of cUTI, including
pyelonephritis, caused by certain bacteria, in adult patients who
have limited treatment options; tebipenem HBr is not
FDA-approved.
- Spero Therapeutics also has an IV-administered next generation
polymyxin product candidate, SPR206, developed from its potentiator
platform, which is in development to treat multi-drug resistant
Gram-negative infections in the hospital setting.
For more information, visit
https://sperotherapeutics.com.
Investor Relations
Contact: Ted JenkinsVice President, Investor
Relations and Strategic FinanceIR@sperotherapeutics.com (617)
798-4039
Media Inquiries:Lora Grassilli,
Health Media RelationsZeno
Grouplora.grassilli@zenogroup.com646-932-3735
Spero Therapeutics (NASDAQ:SPRO)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Spero Therapeutics (NASDAQ:SPRO)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024